Developer docs
API playgroundTry for free, no card

Search company profiles

Syenex

Full company profile

uuid000cktb

Namestring
Syenex
Legal namestring
Syenex
Websiteurl
syenex.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Syenex is a privately held synthetic biology platform company founded in 2022 and headquartered in Evanston, Illinois, that develops next-generation delivery tools for cell and gene therapy drug developers. The company builds enveloped viral vector technologies — including the VivoCell Platform for in vivo T-cell engineering (eliminating ex vivo manipulation in CAR-T manufacturing), UltraCell Technology for improved lentiviral vector productivity, Cell Specific Delivery surface compositions optimized for T-cell targeting, and Programmable Payloads compatible with retroviral integrase-based systems — that address supply chain, quality, and cost bottlenecks in genetic medicine manufacturing.

The company monetizes through licensing, platform access fees, and CDMO integration partnerships, targeting enterprise biotech and pharmaceutical customers developing cell and gene therapies. Its go-to-market combines direct enterprise engagement via website-based intake forms with channel partnerships through CDMO integrations (Bionova Scientific, uBriGene Biosciences) and strategic co-development agreements with clinical-stage therapeutic developers (Leucid Bio) and clinical infrastructure JVs (CTMC, an MD Anderson/Resilience joint venture). Pricing is quote-based and not publicly disclosed, consistent with bespoke enterprise licensing arrangements at early commercialization stage.

Syenex operates with a small multidisciplinary team of approximately 6 named contributors (Co-Founder & CEO Jay Rosanelli, Co-Founder & CSO Josh Leonard, VP R&D Matteo Stoppato, Director of Operations Teresa Nikolich, and Senior Scientists), with AlleyCorp as a disclosed institutional backer. The company pursues an ecosystem strategy anchored on embedded technology integrations across multiple CDMO platforms, with partnerships concentrated in late 2025 and early 2026 indicating active commercial expansion into the cell and gene therapy value chain.

Short descriptiontext

Syenex develops synthetic biology delivery tools — including the VivoCell Platform and UltraCell Technology — for cell and gene therapy drug developers, targeting enterprise biotech, CDMO, and clinical-stage therapeutic companies with licensing and CDMO integration partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEvanston, United States
HQ citystring
Evanston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
synthetic biology delivery, viral vector platforms, cell and gene therapy, lentiviral vector manufacturing, in vivo CAR-T delivery
Industry2 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell and Gene Therapy Delivery Technologies
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing & Platform Access
TypeLicensing Royalties
Description

Syenex provides its delivery technologies and bioengineering systems to drug developers through licensing arrangements and platform access partnerships. Revenue derived from CDMO integrations, technology access fees, and regulatory support services.

syenex.com
2Manufacturing Alliance Revenue
TypeLicensing Royalties
Description

Partnership with Bionova Scientific positions Syenex's delivery technologies as preferred manufacturing solutions, generating revenue through preferred partner status and integration of technologies into manufacturing workflows.

genengnews.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1VivoCell Platform
Description

A next-generation in vivo delivery platform for CAR-T cell engineering and T-cell targeting, enabling cell type specific delivery of genetic medicines.

bioprocessintl.com
Core offering1 text field

Syenex develops and licenses synthetic biology delivery tools and bioengineering platforms for cell and gene therapy developers. Its core VivoCell Platform enables in vivo T-cell engineering that eliminates ex vivo manipulation, while the UltraCell Technology improves lentiviral vector productivity, yield, and cost in GMP manufacturing. The technology is delivered to drug developers through licensing arrangements, CDMO manufacturing integrations, and co-development partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced comparability risk and improved lentiviral vector manufacturability in GMP manufacturing
+2 more records
Product overview1 text field

Syenex is a genetic medicines platform company offering a unified portfolio of delivery technologies for cell and gene therapies. The core offering is the VivoCell Platform, which enables in vivo T-cell engineering. This platform is enhanced by the UltraCell Technology for improved lentiviral vector manufacturing. Supporting technologies include Cell Specific Delivery (optimized for T-cell targeting) and Programmable Payloads (compatible with various cell engineering payloads). The company focuses on bioengineering tools that improve delivery efficiency, scalability, and regulatory pathway support for drug developers.

Product and service2 records
1VivoCell Platform
CategorySynthetic biology delivery platform
Description

A next-generation in vivo delivery platform that enables direct engineering of T-cells within the body, eliminating the need for ex vivo manipulation in CAR-T therapy manufacturing. Targeted at drug developers and therapeutic companies developing cell and gene therapies.

2UltraCell Technology
CategoryLentiviral vector manufacturing technology
Description

Syenex's proprietary next-generation delivery technology integrated into partner CDMO manufacturing platforms to improve lentiviral vector productivity, yield, and manufacturability while reducing costs. Targeted at CDMOs and therapeutic developers requiring scalable lentiviral vector manufacturing.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Strategic manufacturing alliance combining Bionova's proprietary IS-free plasmid DNA manufacturing platform with Syenex's delivery technologies. Addresses critical bottlenecks in pricing, quality, and supply-chain reliability for pDNA. Enables therapeutic developers to progress from early-stage RUO plasmids through GMP manufacturing with reduced comparability risk.

2uBriGene Biosciences
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-16
Description

Strategic partnership integrating Syenex's UltraCell technology into uBriGene's LVV Turbo GMP lentiviral vector manufacturing platform. The integration aims to improve productivity, yield, and reduce costs in lentiviral manufacturing for cell therapy development.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-15
Description

Strategic collaboration to develop in vivo CAR-T cell therapies leveraging Syenex's VivoCell Platform for delivery of Leucid's LEU011 asset. Partnership aims to accelerate clinical development and manufacturing for solid tumor treatment, with potential to shift toward more scalable, off-the-shelf therapy. Supports Leucid's ongoing Phase I/IIa AERIAL trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-08
Description

Partnership between CTMC (joint venture between MD Anderson Cancer Center and Resilience) and Syenex to improve scalability and efficiency of engineered T cell therapies. CTMC utilizes Syenex's bioengineering systems which significantly enhance gene delivery efficiency and manufacturing timelines.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dyno applies AI-driven capsid engineering to develop improved AAV vectors for gene therapy delivery, with partnerships across multiple pharma companies. Comparable to Syenex as an engineered-delivery-platform company targeting cell-type-specific delivery for genetic medicines.

TypeEmerging player
Description

Cellectis develops gene-edited allogeneic CAR-T cell therapies and provides cell engineering platforms to partners. Comparable to Syenex as a gene/cell engineering technology company with both internal programs and external platform partnerships.

TypeDirect peer
Description

Strand develops synthetic biology-based mRNA circuits for cell therapy and oncology, including controllable gene expression systems. Comparable to Syenex as a programmable, synthetic-biology-enabled delivery and gene expression platform for cell and gene therapies.

TypeDirect peer
Description

Acuitas develops lipid nanoparticle (LNP) delivery technology used in approved mRNA therapeutics. Like Syenex, it operates as a delivery technology platform partner rather than a drug developer, licensing its technology to pharma and biotech customers.

TypeBroad incumbent
Description

Editas is a clinical-stage CRISPR gene editing company developing in vivo and ex vivo gene-edited medicines. Comparable to Syenex's broader cell and gene therapy delivery and editing category, though Editas operates as a drug developer with internal programs.

TypeDirect peer
Description

MaxCyte provides electroporation-based delivery technology for cell engineering, with a Flow Electroporation platform used by clinical-stage cell therapy developers. Directly comparable to Syenex as a non-viral delivery technology enabler for cell therapy manufacturing.

TypeEmerging player
Description

Intellia is a clinical-stage developer of in vivo CRISPR/Cas9 gene editing therapies delivered via lipid nanoparticles. Comparable to Syenex as a company advancing in vivo delivery and editing as alternatives to ex vivo cell manipulation.

TypeEmerging player
Description

Verve is developing in vivo gene editing therapies for cardiovascular disease using lipid nanoparticle delivery. Comparable to Syenex's in vivo delivery thesis (VivoCell) as a clinical-stage developer demonstrating in vivo cell engineering as an alternative to ex vivo approaches.

TypeBroad incumbent
Description

CRISPR Therapeutics is a leading clinical-stage gene editing company with approved Casgevy therapy and broad ex vivo / in vivo programs. Comparable to Syenex as a broader cell and gene therapy platform, though CRISPR Therapeutics is much larger and operates as a drug developer.

TypeBroad incumbent
Description

Telesis Bio (formerly Codex DNA) provides synthetic biology tools and automated platforms for DNA synthesis and protein engineering. Comparable to Syenex as a synthetic biology tools company enabling downstream therapeutic development, though operating upstream of the delivery focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syenex

Cell and Gene Therapy Delivery Technologiessyenex.com

Syenex develops synthetic biology delivery tools — including the VivoCell Platform and UltraCell Technology — for cell and gene therapy drug developers, targeting enterprise biotech, CDMO, and clinical-stage therapeutic companies with licensing and CDMO integration partnerships.

What Syenex does

Syenex is a privately held synthetic biology platform company founded in 2022 and headquartered in Evanston, Illinois, that develops next-generation delivery tools for cell and gene therapy drug developers. The company builds enveloped viral vector technologies — including the VivoCell Platform for in vivo T-cell engineering (eliminating ex vivo manipulation in CAR-T manufacturing), UltraCell Technology for improved lentiviral vector productivity, Cell Specific Delivery surface compositions optimized for T-cell targeting, and Programmable Payloads compatible with retroviral integrase-based systems — that address supply chain, quality, and cost bottlenecks in genetic medicine manufacturing.

The company monetizes through licensing, platform access fees, and CDMO integration partnerships, targeting enterprise biotech and pharmaceutical customers developing cell and gene therapies. Its go-to-market combines direct enterprise engagement via website-based intake forms with channel partnerships through CDMO integrations (Bionova Scientific, uBriGene Biosciences) and strategic co-development agreements with clinical-stage therapeutic developers (Leucid Bio) and clinical infrastructure JVs (CTMC, an MD Anderson/Resilience joint venture). Pricing is quote-based and not publicly disclosed, consistent with bespoke enterprise licensing arrangements at early commercialization stage.

Syenex operates with a small multidisciplinary team of approximately 6 named contributors (Co-Founder & CEO Jay Rosanelli, Co-Founder & CSO Josh Leonard, VP R&D Matteo Stoppato, Director of Operations Teresa Nikolich, and Senior Scientists), with AlleyCorp as a disclosed institutional backer. The company pursues an ecosystem strategy anchored on embedded technology integrations across multiple CDMO platforms, with partnerships concentrated in late 2025 and early 2026 indicating active commercial expansion into the cell and gene therapy value chain.

Syenex firmographics

Firmographics
Name
Syenex
Legal name
Syenex
Website
https://syenex.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Syenex develops synthetic biology delivery tools — including the VivoCell Platform and UltraCell Technology — for cell and gene therapy drug developers, targeting enterprise biotech, CDMO, and clinical-stage therapeutic companies with licensing and CDMO integration partnerships.
Ownership category
akta.pro rank

Syenex industry classification

Industry
Product category
Cell and Gene Therapy Delivery Technologies
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Synthetic biology delivery
  • Viral vector platforms
  • Cell and gene therapy
  • Lentiviral vector manufacturing
  • In vivo CAR-T delivery

Where Syenex is headquartered

Location

Headquarters

HQ city
Evanston
HQ country
United States
HQ region
North America

Markets served

Syenex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing & Platform Access: Syenex provides its delivery technologies and bioengineering systems to drug developers through licensing arrangements and platform access partnerships. Revenue derived from CDMO integrations, technology access fees, and regulatory support services.
  2. Manufacturing Alliance Revenue: Partnership with Bionova Scientific positions Syenex's delivery technologies as preferred manufacturing solutions, generating revenue through preferred partner status and integration of technologies into manufacturing workflows.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Syenex product offering

Product offering

Core offering

Syenex develops and licenses synthetic biology delivery tools and bioengineering platforms for cell and gene therapy developers. Its core VivoCell Platform enables in vivo T-cell engineering that eliminates ex vivo manipulation, while the UltraCell Technology improves lentiviral vector productivity, yield, and cost in GMP manufacturing. The technology is delivered to drug developers through licensing arrangements, CDMO manufacturing integrations, and co-development partnerships.

Product overview

Syenex is a genetic medicines platform company offering a unified portfolio of delivery technologies for cell and gene therapies. The core offering is the VivoCell Platform, which enables in vivo T-cell engineering. This platform is enhanced by the UltraCell Technology for improved lentiviral vector manufacturing. Supporting technologies include Cell Specific Delivery (optimized for T-cell targeting) and Programmable Payloads (compatible with various cell engineering payloads). The company focuses on bioengineering tools that improve delivery efficiency, scalability, and regulatory pathway support for drug developers.

Differentiator

Problem solved

Functional benefit

Brands

  • VivoCell Platform: A next-generation in vivo delivery platform for CAR-T cell engineering and T-cell targeting, enabling cell type specific delivery of genetic medicines.

Products and services

  • VivoCell Platform A next-generation in vivo delivery platform that enables direct engineering of T-cells within the body, eliminating the need for ex vivo manipulation in CAR-T therapy manufacturing. Targeted at drug developers and therapeutic companies developing cell and gene therapies.
  • UltraCell Technology Syenex's proprietary next-generation delivery technology integrated into partner CDMO manufacturing platforms to improve lentiviral vector productivity, yield, and manufacturability while reducing costs. Targeted at CDMOs and therapeutic developers requiring scalable lentiviral vector manufacturing.

Quantifiable outcome

  • Reduced comparability risk and improved lentiviral vector manufacturability in GMP manufacturing
  • +2 more outcomes

Companies that use Syenex

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles2 records

Syenex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Syenex partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Bionova ScientificcoreStrategic or Co-development Partner · 8 January 2026Strategic manufacturing alliance combining Bionova's proprietary IS-free plasmid DNA manufacturing platform with Syenex's delivery technologies. Addresses critical bottlenecks in pricing, quality, and supply-chain reliability for pDNA. Enables therapeutic developers to progress from early-stage RUO plasmids through GMP manufacturing with reduced comparability risk.
  • uBriGene BiosciencescoreTechnology or Integration · 16 December 2025Strategic partnership integrating Syenex's UltraCell technology into uBriGene's LVV Turbo GMP lentiviral vector manufacturing platform. The integration aims to improve productivity, yield, and reduce costs in lentiviral manufacturing for cell therapy development.
  • Leucid BiocoreStrategic or Co-development Partner · 15 December 2025Strategic collaboration to develop in vivo CAR-T cell therapies leveraging Syenex's VivoCell Platform for delivery of Leucid's LEU011 asset. Partnership aims to accelerate clinical development and manufacturing for solid tumor treatment, with potential to shift toward more scalable, off-the-shelf therapy. Supports Leucid's ongoing Phase I/IIa AERIAL trial.
  • CTMCcoreStrategic or Co-development Partner · 8 January 2025Partnership between CTMC (joint venture between MD Anderson Cancer Center and Resilience) and Syenex to improve scalability and efficiency of engineered T cell therapies. CTMC utilizes Syenex's bioengineering systems which significantly enhance gene delivery efficiency and manufacturing timelines.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Syenex competitors and assessment

Company assessment

Direct peers

  • Dyno Therapeutics: Dyno applies AI-driven capsid engineering to develop improved AAV vectors for gene therapy delivery, with partnerships across multiple pharma companies. Comparable to Syenex as an engineered-delivery-platform company targeting cell-type-specific delivery for genetic medicines.
  • Strand Therapeutics: Strand develops synthetic biology-based mRNA circuits for cell therapy and oncology, including controllable gene expression systems. Comparable to Syenex as a programmable, synthetic-biology-enabled delivery and gene expression platform for cell and gene therapies.
  • Acuitas Therapeutics: Acuitas develops lipid nanoparticle (LNP) delivery technology used in approved mRNA therapeutics. Like Syenex, it operates as a delivery technology platform partner rather than a drug developer, licensing its technology to pharma and biotech customers.
  • MaxCyte: MaxCyte provides electroporation-based delivery technology for cell engineering, with a Flow Electroporation platform used by clinical-stage cell therapy developers. Directly comparable to Syenex as a non-viral delivery technology enabler for cell therapy manufacturing.

Emerging players

  • Cellectis: Cellectis develops gene-edited allogeneic CAR-T cell therapies and provides cell engineering platforms to partners. Comparable to Syenex as a gene/cell engineering technology company with both internal programs and external platform partnerships.
  • Intellia Therapeutics: Intellia is a clinical-stage developer of in vivo CRISPR/Cas9 gene editing therapies delivered via lipid nanoparticles. Comparable to Syenex as a company advancing in vivo delivery and editing as alternatives to ex vivo cell manipulation.
  • Verve Therapeutics: Verve is developing in vivo gene editing therapies for cardiovascular disease using lipid nanoparticle delivery. Comparable to Syenex's in vivo delivery thesis (VivoCell) as a clinical-stage developer demonstrating in vivo cell engineering as an alternative to ex vivo approaches.

Broad incumbents

  • Editas Medicine: Editas is a clinical-stage CRISPR gene editing company developing in vivo and ex vivo gene-edited medicines. Comparable to Syenex's broader cell and gene therapy delivery and editing category, though Editas operates as a drug developer with internal programs.
  • CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage gene editing company with approved Casgevy therapy and broad ex vivo / in vivo programs. Comparable to Syenex as a broader cell and gene therapy platform, though CRISPR Therapeutics is much larger and operates as a drug developer.
  • Telesis Bio: Telesis Bio (formerly Codex DNA) provides synthetic biology tools and automated platforms for DNA synthesis and protein engineering. Comparable to Syenex as a synthetic biology tools company enabling downstream therapeutic development, though operating upstream of the delivery focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Syenex social profiles

Digital presence

Syenex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syenex leadership team

Management profile

Number of profiles

Profiles6 records

Syenex funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syenex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syenex

What does Syenex do?

Syenex develops and licenses synthetic biology delivery tools and bioengineering platforms for cell and gene therapy developers. Its core VivoCell Platform enables in vivo T-cell engineering that eliminates ex vivo manipulation, while the UltraCell Technology improves lentiviral vector productivity, yield, and cost in GMP manufacturing. The technology is delivered to drug developers through licensing arrangements, CDMO manufacturing integrations, and co-development partnerships.

Is Syenex a public or private company?

Syenex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Syenex founded?

Syenex was founded in 2022. It employs 11 to 50 people.

Where is Syenex based?

Syenex is headquartered in Evanston, United States, in the North America region.

How does Syenex make money?

Two revenue lines are on record. Technology Licensing & Platform Access are the primary driver. The others are manufacturing Alliance Revenue.

Who are Syenex's main competitors?

Direct peers on record are Dyno Therapeutics, Strand Therapeutics, Acuitas Therapeutics and MaxCyte. Emerging players are Cellectis, Intellia Therapeutics and Verve Therapeutics. Broad incumbents are Editas Medicine, CRISPR Therapeutics and Telesis Bio.

Does Syenex have an API?

No public API is recorded for Syenex.

What industry is Syenex in?

Syenex's product category is Cell and Gene Therapy Delivery Technologies. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsBionova Scientific and Syenex Enter Plasmid DNA AllianceBionova Scientific, an Asahi Kasei CDMO, has formed a manufacturing alliance with Syenex, a genetic medicines platform company, to expand global access to DNA plasmids for advanced cell and gene therapies. Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex's delivery platforms, while expanding its off-the-shelf and custom lentiviral vector plasmid system offerings. The partnership integrates Syenex's next-generation delivery technologies into Bionova's development and manufacturing platform.BioSpaceBionova Scientific and Syenex Forge Strategic Alliance to Expand Access to High-Quality Plasmid DNA for Advanced TherapiesBionova Scientific and Syenex announced a strategic manufacturing alliance to expand access to high-quality plasmid DNA for advanced cell and gene therapies. Bionova will serve as the preferred manufacturing partner for Syenex's delivery platforms, addressing bottlenecks in plasmid pricing, quality, and supply-chain reliability. The partnership aims to enable faster progression to commercial manufacturing.BioProcess InternationalLeucid Bio and Syenex team up to advance CAR-T administrationBiotechnology company Leucid Bio announced a strategic collaboration with gene therapy platform firm Syenex to gain access to Syenex's VivoCell Platform for in vivo delivery of Leucid's CAR-T cell assets, including LEU011 which is under development for solid tumors. The platform enables generation of CAR-T cells within the body, bypassing traditional ex vivo processing and logistics challenges associated with current CAR-T administration. Leucid will continue clinically validating LEU011 in the ongoing Phase I/IIa AERIAL trial, which has shown preliminary evidence of good tolerability and disease control in patients with relapsed/refractory solid tumors.PharmiWeb.comLeucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell EngineeringLeucid Bio and Syenex announced a strategic collaboration to use Syenex's VivoCell Platform for in vivo delivery of Leucid's CAR-T therapy LEU011 in treating solid tumours. The non-exclusive agreement enables CAR-T cell engineering directly within the body, eliminating the need for complex ex vivo cell processing and logistics. The collaboration aims to accelerate Leucid's in vivo programme toward IND-enabling studies while the company continues its ongoing Phase I/IIa AERIAL trial for LEU011.BioSpaceuBriGene Launches LVV Turbo(TM) - Its Next-Generation GMP Lentiviral Vector Manufacturing Platform - and announces a Strategic Partnership with Syenex for integration of its UltraCell(TM) TechnologyuBriGene Biosciences launched LVV Turbo™, its next-generation GMP lentiviral vector manufacturing platform, and announced a strategic partnership with Syenex to integrate UltraCell™ technology into the workflow. The combined platform incorporates a high-productivity suspension cell line, a closed downstream purification process, and UltraCell™ technology, delivering up to five times higher transduction titers and enabling up to 1,500 CAR-T doses from a 20-liter run while substantially reducing cost of goods sold for cell therapy developers.PharmiWeb.comLeucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell EngineeringLeucid Bio and Syenex have announced a strategic collaboration to enable in vivo delivery of Leucid’s CAR-T therapy candidate LEU011 using Syenex’s VivoCell Platform, with the goal of transforming conventional ex vivo CAR-T processing into a simpler, potentially off-the-shelf administration approach. The collaboration aims to accelerate Leucid’s in vivo program from in vitro proof-of-concept to IND-enabling studies while supporting the ongoing Phase I/IIa AERIAL trial of LEU011 in patients with relapsed/refractory solid tumours. LEU011 has demonstrated good tolerability and functional activity in early trial data, and the partnership is expected to unlock the therapeutic potential of Leucid’s lateral CAR-T platform.PR NewswireLeucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell EngineeringLeucid Bio and Syenex announced a strategic collaboration to use Syenex's VivoCell Platform for precise in vivo delivery of Leucid's CAR-T therapy LEU011 targeting solid tumours. The partnership aims to eliminate the need for complex ex vivo cell processing by enabling direct in vivo CAR-T cell engineering, accelerating the programme from in vitro proof-of-concept toward IND-enabling studies. LEU011 is currently being evaluated in the ongoing Phase I/IIa AERIAL trial for relapsed/refractory solid tumours.Towards HealthcareCell and Gene Therapy Tools and Reagents Top Companies and Strategic InvolvementsThe global cell and gene therapy tools and reagents market reached US$ 11.12 billion in 2025 and is projected to grow to approximately US$ 27.3 billion by 2034, expanding at a CAGR of 10.76%. Notable recent developments include Sartorius Stedim Biotech investing $3 million in Nanotein Technologies for its NanoSpark platform, and Hologen providing $430 million in funding to MeiraGTx for the development of an investigational AAV-GAD gene therapy for Parkinson's disease. Other active developments include product launches by CellFE and Asimov, and a collaboration between CTMC and Syenex to expand lentiviral and retroviral vector manufacturing platforms.